Evidence map›Paper›PMID 32967963›Full record

ArticleJournal of virology2020

Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.

Anna Godi, Dolcibella Boampong, Busayo Elegunde, Kavita Panwar, Maxime Fleury, Shaowei Li, Qinjian Zhao, Ningshao Xia, Neil D Christensen, Simon Beddows

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Anna GodiVirus Reference Department, Public Health England, London, UK.
Dolcibella BoampongVirus Reference Department, Public Health England, London, UK.
Busayo ElegundeVirus Reference Department, Public Health England, London, UK.
Kavita PanwarVirus Reference Department, Public Health England, London, UK.
Maxime FleuryGroupe d'étude des interactions Hôte-Pathogène, Université d'Angers, Angers, France.
Shaowei LiNational Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Fujian, China.
Qinjian ZhaoNational Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Fujian, China.
Ningshao XiaNational Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Fujian, China.
Neil D ChristensenJake Gittlen Laboratories for Cancer Research, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Simon BeddowsVirus Reference Department, Public Health England, London, UK simon.beddows@phe.gov.uk.ORCID 0000-0002-6879-6215
Public Health England · GBXiamen University · CNPennsylvania State University · USUniversité d'Angers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) is the causative agent of cervical and other epithelial cancers. Naturally occurring variants of HPV have been classified into lineages and sublineages based on their whole-genome sequences, but little is known about the impact of this diversity on the structure and function of viral gene products. The HPV capsid is an icosahedral lattice comprising 72 pentamers of the major capsid protein (L1) and the associated minor capsid protein (L2). We investigated the potential impact of this genome variation on the capsid antigenicity of lineage and sublineage variants of seven vaccine-relevant, oncogenic HPV genotypes by using a large panel of monoclonal antibodies (MAbs) raised against the L1 proteins of lineage A antigens. Each genotype had at least one variant that displayed a ≥4-fold reduced neutralizing antibody sensitivity against at least one MAb, demonstrating that naturally occurring variation can affect one or more functional antigenic determinants on the HPV capsid. For HPV16, HPV18, HPV31, and HPV45, the overall impact was of a low magnitude. For HPV33 (sublineages A2 and A3 and lineages B and C), HPV52 (lineage D), and HPV58 (lineage C), however, variant residues in the indicated lineages and sublineages reduced their sensitivity to neutralization by all MAbs by up to 1,000-fold, suggesting the presence of key antigenic determinants on the surface of these capsids. These determinants were resolved further by site-directed mutagenesis. These data improve our understanding of the impact of naturally occurring variation on the antigenicity of the HPV capsid of vaccine-relevant oncogenic HPV genotypes.

Indexed as

GenotypeAlphapapillomavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCapsid ProteinsEpitopesGenes, ViralGenetic VariationHuman papillomavirus 16Human papillomavirus 31HumansNeutralization TestsOncogene Proteins, ViralOncogenesAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCapsid ProteinsEpitopesHPV L1 protein, Human papillomavirusOncogene Proteins, ViralPapillomavirus Vaccinesantigenicityhuman papillomaviruslineagemonoclonal antibodiesneutralizationvariant

Identifiers

PMID32967963
PMCPMC7925199
OpenAlexW3088524311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.